title: [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
abstract: Molecular identification of tumor antigens has made possible to develop tumor-specific immunotherapy. Provenge was approved by FDA as a first therapeutic drug for cancer in 2010. A line of drug candidates is in late phase clinical trials as therapeutic vaccine for patients with solid tumors. Adoptive immunotherapy with tumor-specific T cells demonstrated clinical effectiveness in patients with advanced malignancy such as metastatic melanoma and synovial cell sarcoma. Genetically engineered T cells were administrated to cancer patients with promising results and may extend the application of adoptive immunotherapy of tumor. Although recent findings in tumor biology and immunity suggest the integrated immune response against tumor with special emphasis on inhibitory mechanism, we are unmistakably witnessing the moment that immunotherapy of cancer becomes a medical option.
authors.affiliation: Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ikeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shiku
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines